Innovation Pharmaceuticals Inc (IPIX): Escrow comes to mind. Or maybe they&#39...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	230
Posts	21512
Boards Moderated	2
Alias Born	08/03/2006

BooDog

Re: MinnieM post# 228089

Monday, 05/14/2018 8:06:48 AM

Monday, May 14, 2018 8:06:48 AM

Escrow comes to mind. Or maybe they're looking at a new hire for phase 3 and marketing of Brilacidin OM. And it does look like they may have sold some or a good portion if Aspire was just about the only one selling. Glad I soaked up a few.

Plenty of speculation.

Message in reply to:

Look at my full quote:

Quote:
however, in no event shall the Purchase Amount of a Regular Purchase exceed Five Hundred Thousand Dollars ($500,000) per Business Day unless the Buyer and the Company mutually agree. The Company and the Buyer may mutually agree to increase the number of Purchase Shares that may be sold per Regular Purchase to as much as an additional 2,000,000 Purchase Shares per Business Day. The Company may deliver additional Purchase Notices to the Buyer from time to time so long as the most recent purchase has been completed. The share amounts in the first and second sentences of this Section 1(b) shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split, or other similar transaction.

They can agree to go outside the parameters of a regular purchase. At least, that's how I read it.

It's unlikely you'd see when the sales are made to aspire since they may not sell it on the same day. Volume won't be an accurate way to judge how much has been sold to them and when.

Also, look at what I'm speculating the funds may have been used for.

Needed for attornies reviewing final contracts on a Brilacidin deal.

Needed to make final payments to CRO and analyze unblinded Prurisol data. This was one of my thoughts as well so they don't fully drain the kitty

A couple posts that I want to keep in place...

Posted by: MackG
In reply to: None Date:5/11/2018 8:30:10 AM
Post #227802 of 228133

As the science of IP's three principal drug compounds has progressed successfully, the intrinsic value of the company has grown tremendously. However, because operations are being financed through the arrangement with Aspire Capitol, an artificial downward selling pressure has caused the share price to fall dramatically. This price to value disconnect has presented us with a pass-through beneficiary opportunity for those of us who have continued to purchase shares at a deep discount to their true value. This has created the potential for a unique wealth creation opportunity for buyers who have done their DD and have a grasp of the value vs. share price dynamic which is explained by the way the company have been capitalized. Yes, there has been dilution because of this arrangement, but the advantage to investors far supersedes that downside for those who have continued to build their position at bargain basement prices. We'll soon seen major news that will make this downward selling pressure go away and the share price begin to rise dramatically. How high is anybody's guess, but this much I'm sure of -- in two to three years time there will be many here who will make millions. I look forward to our celebration of the success of IPIX and the tremendous relief their drugs will bring to patients who suffer from the afflictions they address. So, get 'em while you can, my friends. It's onward and upward from here. All IMO.

petemantx Thursday, 05/10/18 04:43:20 PM
Re: None 0
Post # of 228140

REVISED REVISED post
Your post perfectly illustrates the point I made that IMO all your facts were indeed far off base.

1. Leo came over from a scam. No, Leo was hired into a company that was a scam and as soon as he realized everything was balls up (that doesn't just happen overnight) he left. Show me evidence that he made out financially from his time at this company. I don't think you will find any evidence of that, so why would he have been part of a scam?

2. Aruda shares were a way to funnel cash out of IPIX. No, Cellceutix made an administrative error in the beginning days in the contract they signed Aruda to and forgot to put in the clause that he was providing no design input to Kevetrin and Prurisol and so they got caught in a quasi-BS legal play and had to pay Aruda shares as if he was a co-developer of the drugs. Menon paid the shares to Aruda out of his own holding of stock, so stockholders lost $0 on this situation.

3. Leo BOD appts and gifting shares to his son immaterial as whose business is it what Leo does with his personal shares? As to the BOD appts, you had a company of about 10 people or less so are you going to bring in priced board members to do nothing? All that was happening was pre-clinical research. Bottom line, BS FUD topics.

4. PolyMedix assets worthless. If I believed this I would hope someone would commit me to an insane asylum. Look up PolyMedix, the founder was a genius in a number of areas, they teamed up with one of the finest medical depts in the country at U of Penn., and the architect of the Brilacidin molecule, Dr William DeGrado (attached is a link to his profile from U of Calif San Francisco) http://www.ipharminc.com/new-blog/2017/11/21/...rug-design
Dr. De Grado is one of the greatest biological chemical engineers in the world and is the principal speaker at a conference linked below and which appears on the IPIX website (go to Newsroom, Blog, then scroll down to the 11/21/2007 site)and the referenced presentation will show why he is considered so highly in his field, a portion of which he started by developing synthetic defensin protein mimetics.

To begin with, PolyM went bankrupt because they had MASSIVE debt (IPIX has none) and chose to send thru clinical trials a drug that failed and thus brought the company to BK due to financial problems. PolyM had put Brilacidin thru a P2 trial and had approval from the FDA for a P2b trial that was to begin in 2013 when PolyM had the money to run the trial. They had also identified B as a strong OM candidate but the article I read said they planned on using it as a topical treatment for OM. Dr. M and Leo learned of the availability of the company pipeline of developmental synthetics and Dr. M recognized the broad spectrum applications of Brilacidin. The acquisition one day will be recognized as one of the greatest "steals" in biotech history as Brilacidin has the potential to rival Humira as the highest grossing drug in the world should B prove able to perform in the many broad areas in which indications say it should be excellent. To date, it has shined in EVERY indication tested to include both antibiotic and anti-inflammatory. The PolyM acquisition was strictly for Brilacidin and BP overlooked it or it had not yet reached a significant assurance of success for any to go after it.

Saying PolyMedix products are worthless equates with saying that the Apple IPhone was a failure and of no consequence to Apple.

5. Aborting the ABASSI Ph3 Antibiotic trial Strictly a mgt decision that preferred to advance multiple products thru trials rather than putting all of one's eggs in one basket as that was what would have been required to allot $30MM to the ABASSI Ph3. As it is, due to this shrewd decision by mgt, we have affirmed B works amazingly well in IBD (Irritable Bowel Disorders) as affirmed by the pictures that showed not only was the Ulcerative Colitis symptoms relieved but the condition was cured, B works exceeding well for Oral Mucositis and positions B in the lead position to have this $1B+ market to themselves, Prurisol is soon to release P2B top line results regarding Psoriasis and IMO we will rival the biologics in effectiveness. Consider the effectiveness along with a much lower cost basis and nearly perfect safety profile and Prurisol should become the leading Psoriasis treatment prescribed in a $10B+ market. All in all, I would say mgt should have been given an award for their decision to follow this path rather than go all-or-nothing on a P3 ABASSI trial.

Another major statement of the value of our pipeline is the fact that we know we have 20+ CDAs so obviously BP is highly aware of our pipeline and none of them want to be left out of possibly putting in an offer as the pipeline IMO can be ranked among the greatest (if not the greatest) in history with 3 blockbuster drugs spanning a wide scope of medical conditions with total revenue targets exceeding $100B. All in all, I'd say that speaks pretty damn loudly for a small startup with about 10 employees.

6. K did not work Here again, whose word should one take, yours or Dr. Menon's, the developer of Kevetrin and the project leader for 2 current Eli Lily $1B+ cancer drugs? Dr. M said he believes Kevetrin will prove effective on possibly 50% of cancers, compared it to salt or sugar in the kitchen as it can combine with everything, had its Phase 1 clinical trial for safety stopped after 3 years because they couldn't obtain any negative side effects on PHASE 4 TERMINAL PATIENTS (think how weak their systems were coming into the trial) even though the dosing had gone from 10 units to 800 units, and, the unbelievable, it showed to activate the pathway for the p53 gene, the GUARDIAN ANGEL gene, the most researched topic in medical history, the gene regarded as the Holy Grail of cancer, and they realized that with its rapid expulsion from the body (thus no systemic buildup, a great thing for cancer treatments) that they had to formulate it into a pill that could be taken many times a day and thus they are doing that now. They had already been working on the oral formulation since 2016 and just recently contracted EVONIK, a German 38K employee, 100 country, 14B Euro, drug manufacturer to mfr the B-OM sachet with Brilacidin in the powder form. Anybody think EVONIK also has the technology to make gels/foams/creams/pills/IV/etc?

"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.